In the wake of cannabis legalization, a team of scientists at the Research Institute of the McGill University Health Centre and McGill University have delivered encouraging news for chronic pain sufferers by pinpointing the effective dose of marijuana plant extract cannabidiol for safe pain relief without the typical “High” or euphoria produced by the THC. The findings of their study have been published in the journal PAIN. Cannabis indica and sativa are the two main cannabis strains that produce the pharmacological principles known as tetrahydrocannabinol and cannabidiol.
Dr. Gabriella Gobbi’s team demonstrated that CBD does not act on the CB1 cannabinoid receptors like THC but through the mechanism that binds specific receptors involved in anxiety and pain.
Researchers were able to extrapolate the exact dosage of CBD displaying analgesic and antianxiety properties without the risk of addiction and euphoria classically produced by the THC. “We found in animal models of chronic pain that low doses of CBD administered for seven days alleviate both pain and anxiety, two symptoms often associated in neuropathic or chronic pain,” says first author of the study Danilo De Gregorio, a post-doctoral fellow at McGill University in Dr. Gobbi’s laboratory.